FDA approves Atossa endoxifen for “expanded access” preop cancer therapy

Atossa Genetics (NASDAQ:ATOS) announces that the FDA has approved an “expanded access” of Atossa’s oral Endoxifen in the preoperative setting in a U.S. patient awaiting surgery for breast cancer.

Sometimes called “compassionate use,” expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials.

https://seekingalpha.com/news/3413877-fda-approves-atossa-genetics-endoxifen-expanded-access-preoperative-systemic-endocrine